Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 15 versus ADDERALL XR 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 15 versus ADDERALL XR 25.
ADDERALL 15 vs ADDERALL XR 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Adderall XR is a combination of dextroamphetamine and amphetamine, which are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, resulting in increased synaptic concentrations. This leads to CNS stimulation.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
20-60 mg orally once daily in the morning; starting dose 20 mg, titrate weekly by 10-20 mg based on response and tolerability.
None Documented
None Documented
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Dextroamphetamine: 10-13 hours; levoamphetamine: 11-14 hours. Effective half-life supports once-daily dosing with extended duration.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
Renal: approximately 90% (30-40% unchanged, remainder as metabolites); fecal: minimal (<2%) via biliary elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant